- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04888442
Phase I Study of pCAR-19B in the Treatment of Adult CD19-positive Relapsed/Refractory B-ALL
May 12, 2021 updated by: Chongqing Precision Biotech Co., Ltd
A Phase I Clinical Study of Anti-CD19 CAR-T Therapy (pCAR-19B) in the Treatment of Adult CD19-positive Relapsed/Refractory B-ALL
This is a phase I clinical study to evaluate the safety and tolerability of pCAR-19B in adults with relapsed or refractory B-ALL, and to obtain the maximum tolerated dose of pCAR-19B and phase II Recommended dose.
Study Overview
Status
Recruiting
Intervention / Treatment
Detailed Description
This is a single-center, single-arm, open-label study.
The study plans to set up 3 dose groups, adopting a dose-escalating 3+3 design, and plan to recruit about 9-18 adults with relapsed or refractory B-ALL.pCAR-19B will be infused to the subject by intravenous infusion.
Study Type
Interventional
Enrollment (Anticipated)
18
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Xiaoxi zhou, M.D
- Phone Number: 86-27-83665027
- Email: cello316@163.com
Study Contact Backup
- Name: Liang Huang, M.D
- Phone Number: 86-27-63639810
- Email: lhuang@tjh.tjmu.edu.cn
Study Locations
-
-
Hubei
-
Wuhan, Hubei, China
- Recruiting
- Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology
-
Contact:
- Liang Huang, M.D
- Phone Number: 86-27-63639810
- Email: lhuang@tjh.tjmu.edu.cn
-
Contact:
- Xiaoxi Zhou, M.D
- Phone Number: 86-27-83665027
-
Principal Investigator:
- Jianfeng zhou, M.D. Ph.D
-
Sub-Investigator:
- Xiaoxi Zhou, M.D
-
Sub-Investigator:
- Liang Huang, M.D
-
Sub-Investigator:
- Jia Wei, M.D
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
22 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
Diagnosed with B-ALL,and meet one of the following conditions:
- First-line or multiple-line salvage chemotherapy did not achieve complete remission;
- Early relapse after complete remission (<12 months), or late relapse after complete remission (≥12 months) and complete remission has not been achieved after 1 course of treatment;
- Relapse after autologous or allogeneic hematopoietic stem cell transplantation;
- Ph+ALL patients should also receive at least two TKI treatments;
For allogeneic hematopoietic stem cell transplant subjects, the following conditions must be met:
- Allo-HSCT takes ≥6 months before pCAR-19B infusion;
- No GVHD of grade 2 or above occurred within 2 weeks before PBMC collection;
- Express CD19;
- 22~70 years old, no gender limit;
- The expected survival time is more than 12 weeks;
- KPS>60;
- No serious mental disorders;
The function of important organs is basically normal:
- Heart function: echocardiography indicates that the cardiac ejection fraction is ≥50%, and the electrocardiogram has no obvious abnormalities;
- Renal function: serum creatinine≤2.0×ULN;
- Liver function: ALT and AST ≤3.0×ULN;
- Total bilirubin and alkaline phosphatase≤2.0×ULN (Gilbert syndrome ≤ 3.0×ULN);
- Blood oxygen saturation>92%.
- Have standards for apheresis or venous blood collection, and no other cell collection contraindications;
- The patient himself or his guardian agrees to participate in the clinical trial and signs the ICF, indicating that he understands the purpose and procedures of the clinical trial and is willing to participate in the research.
Exclusion Criteria:
- With central nervous system disease at the time of screening;
- Have received CAR-T therapy or other genetically modified cell therapy;
- Participated in other clinical studies within 1 month before screening;
- Have received the following anti-tumor treatments before screening: received chemotherapy, targeted therapy or other experimental drug treatments within 14 days or at least 5 half-lives (whichever is shorter);
- Have received a live attenuated vaccine within 4 weeks before screening;
- Cerebrovascular accident or seizure occurred within 6 months before signing the ICF;
Suffered from any of the following heart diseases:
- NYHA stage III or IV congestive heart failure;
- Myocardial infarction or CABG occurred ≤6 months before enrollment;
- Clinically significant ventricular arrhythmia, or history of unexplained syncope (except for cases caused by vasovagal or dehydration);
- History of severe non-ischemic cardiomyopathy.
- Uncontrollable infection in the 2 weeks before screening;
- Active autoimmune diseases;
- Patients with malignant tumors other than acute lymphoblastic leukemia within 5 years before screening, except for fully treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, local prostate cancer after radical resection, and duct in situ after radical resection cancer;
- HBsAg or HBcAb positive and HBV DNA is greater than the normal range; HCV antibody is positive and HCV RNA greater than the normal range; HIV antibody positive; syphilis positive; CMV DNA positive;
- Women who are pregnant or breastfeeding, and male or female subjects who plan to have children within 1 year after receiving pCAR-19B cell reinfusion;
- Other situations considered by the researcher to be unsuitable to participate in the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: pCAR-19B cells
Infusion of pCAR-19B cells by dose-escalating
|
Drug: pCAR-19B cells; Administration method: intravenous infusion; Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Adverse events after pCAR-19B infusion [Safety and Tolerability]
Time Frame: 28 days
|
Therapy-related adverse events were recorded and assessed according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE, Version 5.0)
|
28 days
|
Obtain the maximum tolerated dose of pCAR-19B cells[Safety and Tolerability]
Time Frame: 28 days
|
Dose-limiting toxicity after cell infusion
|
28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
CMAX of pCAR-19B cells [Cell dynamics]
Time Frame: 3 months
|
CMAX is defined as the highest concentration of pCAR-19B cells expanded in peripheral blood
|
3 months
|
TMAX of pCAR-19B cells [Cell dynamics]
Time Frame: 3 months
|
TMAX is defined as the time to reach the highest concentration
|
3 months
|
Objective response rate after pCAR-19B infusion [Effectiveness]
Time Frame: 3 months
|
Objective response rate includes CR, CRi
|
3 months
|
AUCS of pCAR-19B cells [Cell dynamics]
Time Frame: 3 months
|
AUCS is defined as the area under the curve in 28 days and 90 days
|
3 months
|
Pharmacodynamics of pCAR-19B cells[Cell dynamics]
Time Frame: 3 months
|
Cytokines such as hs-CRP, IL-6 levels
|
3 months
|
Immunogenicity of pCAR-19B cells
Time Frame: 3 months
|
Anti-CAR antibody
|
3 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Jianfeng Zhou, M.D. Ph.D, Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 26, 2020
Primary Completion (Anticipated)
January 30, 2022
Study Completion (Anticipated)
March 28, 2022
Study Registration Dates
First Submitted
May 12, 2021
First Submitted That Met QC Criteria
May 12, 2021
First Posted (Actual)
May 17, 2021
Study Record Updates
Last Update Posted (Actual)
May 17, 2021
Last Update Submitted That Met QC Criteria
May 12, 2021
Last Verified
May 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PB02
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Lymphoblastic Leukemia, in Relapse
-
Institut Paoli-CalmettesINATHERYSRecruitingAcute Lymphoblastic Leukemia, in Relapse | Acute Myeloid Leukemia, in Relapse | Mixed Phenotype Acute Leukemia | Acute Lymphoblastic Leukemia Recurrent | Acute Myeloid Leukaemia RecurrentFrance
-
Federal Research Institute of Pediatric Hematology...RecruitingAcute Myeloid Leukemia | Myelodysplastic Syndromes | Acute Lymphoblastic Leukemia, in Relapse | Non-hodgkin Lymphoma | High Risk Acute Myeloid Leukemia | High Risk Acute Lymphoblastic Leukemia | Acute Biphenotypic Leukemia in RelapseRussian Federation
-
Beijing Boren HospitalRecruitingAcute Lymphoblastic Leukemia, Pediatric | Acute Lymphoblastic Leukemia, in Relapse | Refractory Acute Lymphoblastic LeukemiaChina
-
Andrew E. Place, MDUniversity of Colorado, Denver; AbbVie; Boston Children's Hospital; Gateway for... and other collaboratorsRecruitingAcute Lymphoblastic Leukemia, in Relapse | Therapy-Related Myelodysplastic Syndrome | Acute Leukemia of Ambiguous Lineage | Acute Leukemia of Ambiguous Lineage in Relapse | Myelodysplastic Syndromes, Previously Treated | Acute Lymphoblastic Leukemia With Failed Remission | Myelodysplastic Syndromes... and other conditionsUnited States
-
Group for Research in Adult Acute Lymphoblastic...AmgenUnknownAcute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia With Failed RemissionFrance
-
University of BirminghamAstraZeneca; Cancer Research UKTerminatedAcute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia, Pediatric | Acute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia, Adult | Acute Lymphoblastic Leukemia RecurrentUnited Kingdom, Denmark, Netherlands
-
St. Jude Children's Research HospitalActive, not recruitingAcute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia, RefractoryUnited States
-
Beijing Boren HospitalRecruitingAcute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia, in Relapse | Refractory Acute Lymphoblastic LeukemiaChina
-
Assistance Publique - Hôpitaux de ParisRecruitingAcute Lymphoblastic Leukemia, in Relapse | B Acute Lymphoblastic LeukemiaFrance
-
University College, LondonNot yet recruitingAcute Lymphoblastic Leukemia, Pediatric | Acute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia, Adult | Acute Lymphoblastic Leukemia With Failed Remission | Acute Lymphoblastic Leukemia Not Having Achieved Remission
Clinical Trials on pCAR-19B cells
-
Chongqing Precision Biotech Co., LtdRecruitingAcute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | Relapsed Pediatric ALLChina
-
Chongqing Precision Biotech Co., LtdCompletedAcute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | Relapsed Pediatric ALLChina
-
PersonGen BioTherapeutics (Suzhou) Co., Ltd.Anhui Provincial HospitalUnknownFollicular Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Acute Lymphocytic Leukemia | Diffuse Large Cell Lymphoma | B-cell Prolymphocytic LeukemiaChina
-
PersonGen BioTherapeutics (Suzhou) Co., Ltd.Anhui Provincial Hospital; The First People's Hospital of Hefei; Hefei Binhu...UnknownFollicular Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Acute Lymphocytic Leukemia | Diffuse Large Cell Lymphoma | B-cell Prolymphocytic LeukemiaChina
-
Medical College of WisconsinMiltenyi Biomedicine GmbHActive, not recruitingB-cell Chronic Lymphocytic Leukemia | B-cell Non Hodgkin LymphomaUnited States
-
University College, LondonUnknownTendinopathy | Achilles Tendinitis | Achilles Degeneration | Achilles Tendinitis, Right Leg | Achilles Tendon Thickening | Achilles Tendinitis, Left LegUnited Kingdom
-
Chongqing Public Health Medical CenterZhejiang Qixin Biotech; Chongqing Sidemu BiotechUnknown
-
Hadassah Medical OrganizationCompletedAmyotrophic Lateral Sclerosis
-
American CryoStem CorporationTerminatedMultiple SclerosisCayman Islands
-
UNC Lineberger Comprehensive Cancer CenterRecruitingNeoplasms | Immune System Diseases | Neoplasms by Histologic Type | Lymphoma | Lymphoproliferative Disorders | Lymphatic Diseases | Immunoproliferative Disorders | Lymphoma, Non-HodgkinUnited States